about
Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI InhibitorsThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesDiscovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography †Impact of linker strain and flexibility in the design of a fragment-based inhibitorFragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitorsIntegrated biophysical approach to fragment screening and validation for fragment-based lead discoveryA method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligandDiscovery of fragment molecules that bind the human peroxiredoxin 5 active siteAdvances in Nuclear Magnetic Resonance for Drug Discovery.Phosphate binding sites identification in protein structures.The Seattle Structural Genomics Center for Infectious Disease (SSGCID).Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesisDesign of a fragment library that maximally represents available chemical space.C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.Fragment-based drug discovery using NMR spectroscopyTherapeutic approaches to preventing cell death in Huntington diseaseHigh-throughput fragment screening by affinity LC-MS.Weak affinity chromatography for evaluation of stereoisomers in early drug discovery.Unexpected stereochemical tolerance for the biological activity of tyroscherin.Fragment-based approaches to enzyme inhibitionActivation pathway of Src kinase reveals intermediate states as targets for drug designDynamic Protein Interaction Networks and New Structural Paradigms in Signaling.Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping.Adenylating enzymes in Mycobacterium tuberculosis as drug targets.Fragment-based drug discovery using the SHAPES method.Probing secondary interactions in biomolecular recognition by dynamic combinatorial chemistry.Fragment-based lead discovery: challenges and opportunities.Targeting enzyme inhibitors in drug discovery.Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments.STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis.Design of tRNA(Lys)3 ligands: fragment evolution and linker selection guided by NMR spectroscopy.A detective story in drug discovery: elucidation of a screening artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase.Catalytic activation of pre-substrates via dynamic fragment assembly on protein templates.Drug discovery: A question of library design
P2860
Q26823990-A6835B63-29BC-42C9-8F4B-A38A5E950A70Q27489856-0D390FBE-46E2-4317-9A68-E50054653D79Q27646546-8AD9DFC4-2E58-4E6F-A2AB-AF26AB3AC638Q27655287-E5D33741-5894-44A7-B4DF-CAB536B76A5EQ27663569-1831A75E-7837-4D1D-B352-0795BE20600EQ27679154-2A04BE94-21F7-4BBD-8561-619659BF4D0CQ27684920-3EE4F7B9-0CBA-4F61-A495-3BD1238DFD2AQ28473225-D393B811-6285-47BD-81A8-CBF47F5E263CQ30387229-C5E9B989-7D80-4C4E-8D99-FBCDF52D20C9Q30395251-2AD47F2C-98CC-4330-8F30-79824EDB2788Q33802114-1A5B8E33-3CE4-4745-85EC-01EAB1984A6CQ33877498-39B3129C-6DA0-487A-84CB-6F09FFA9DFFDQ33972623-41F42976-CE66-4367-B15B-A68C5527C1B5Q34162668-9C18022A-C705-402E-ACA3-94FB66988C56Q34345451-B8465427-3501-490C-9958-6A8C94A825C3Q34411338-C0033253-A18C-49D1-A578-7D8C4D0902D5Q34415618-9F70703E-D340-4E8D-A57C-465480672ED5Q34616425-0A6B04F5-E1DF-4D37-AB61-EE33DB12F038Q34666741-6C5CA8D2-2DD3-4932-90F8-419CAEE7F36DQ34706518-6BD73ACD-F147-46D6-B2A5-B5140535492AQ35738216-5FDC5170-E589-46D2-A087-8D54E451B8C6Q35938545-216C0721-1887-43DE-909B-DBBAD09D0565Q37147032-49232B1B-3431-4095-9858-2A54742010A7Q37257062-F54C82B0-688D-4C3C-822C-142EE2D7FA79Q38089130-941F7427-2BB4-4256-8D7F-C09693F52A7EQ38199945-CE7E0A38-A617-4CE8-BA6C-92BED77BA0F0Q39731911-2F4D9EE3-0B2B-42AB-85CA-B9E5FB7D945DQ40197049-683457B2-346B-4198-AC12-7943B9325177Q41089471-B456E1A5-3CDF-4652-937A-5254887A5461Q42234685-75E9D003-E002-479E-B5E5-A0D2A6093C65Q45328799-3F8A19E1-F255-4297-BB6A-04A7B8F4D137Q50987171-5D19AD9F-F7EA-4B7D-8FB9-FED171D2B1F7Q52872220-DF9B44B2-AA10-49A5-8C28-9D77B28840FEQ57540680-2C4F75E2-A053-4CE9-AE03-C03A439FC839
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Fragment-based lead discovery: a chemical update.
@ast
Fragment-based lead discovery: a chemical update.
@en
type
label
Fragment-based lead discovery: a chemical update.
@ast
Fragment-based lead discovery: a chemical update.
@en
prefLabel
Fragment-based lead discovery: a chemical update.
@ast
Fragment-based lead discovery: a chemical update.
@en
P1476
Fragment-based lead discovery: a chemical update.
@en
P2093
Daniel A Erlanson
P304
P356
10.1016/J.COPBIO.2006.10.007
P577
2006-11-03T00:00:00Z